laser, respectively. Improvement in VA was comparable in the sham and prompt laser and both ranibizumab treatment groups at 1 and 2 years in the subset of 273 eyes that were pseudophakic at baseline. In the 62 pseudophakic eyes at baseline treated with triamcinoline and prompt laser, VA improvements were better than for phakic eyes and comparable to that of the pseudophakic eyes in the ranibizumab groups and superior to that of pseudophakic eyes treated with sham and prompt laser at years 1 and 2. In terms of safety, no systemic events attributable to study treatments were observed. However, injection-related endophthalmitis occurred in three eyes (0.8 %) with ranibizumab treatment while increased intraocular pressure (IOP) and cataract surgery were more frequent in the triamcinolone group. RISE (NCT00473330) and RIDE (NCT00473382) were two parallel, multicentre, double-masked, sham injection-controlled, randomized trials with identical methodologies. 2 Adult patients with DME vision loss (BCVA)
20/40-20/320 Snellen equivalent and central subfield thickness ≥275 µm on time-domain optical coherence tomography (OCT) were recruited.
Patients received either monthly intravitreal injections of ranibizumab (0.5 or 0.3 mg) or sham injections. Macular laser was available perprotocol-specific criteria. The main outcome measure was the proportion of patients who gained ≥15 ETDRS letters in BCVA at 24 months from baseline. In the RISE study, a total of 377 patients were randomized (0.3 mg ranibizumab n=125, 0.5 mg ranibizumab n=125, sham n=127).
At month 24, significantly more patients treated with ranibizumab gained ≥15 letters compared with the sham group (see Table 1 ). A total of 382 patients were randomized in RIDE, (0.3 mg ranibizumab n=125, 0.5 mg ranibizumab n=127, sham n=130). The results indicated that significantly more patients treated with ranibizumab gained ≥15 letters versus shamtreated patients (see Table 1 ).
In addition, in the ranibizumab groups, retinopathy generally improved as did macular edema. Furthermore, fewer macular laser procedures were performed in ranibizumab-treated patients than sham patients (over 24 months, mean 0.3 -0.8 versus 1.8 and 1.6, respectively).
Endophthalmitis was observed in four ranibizumab patients, but overall ocular safety was consistent with previous studies. The possible effects from systemic VEGF inhibition, namely total incidence of deaths from vascular or unknown causes, nonfatal myocardial infarctions, and nonfatal cerebrovascular accidents occurred in 4.9 and 5.5 % of sham patients and 2.4 to 8.8 % of ranibizumab patients. Dose-dependent increases in stroke was observed in the ranibizumab-treatment groups.
Aflibercept
Aflibercept was compared with laser treatment in two parallel, doublemasked, randomized, phase III, 52-week trials with similar design.
3 VISTADME (NCT01363440) was conducted across 54 sites in the US and VIVIDDME (NCT01331681) at 73 sites in Europe, Japan, and Australia. In total, 872 patients (eyes) with type 1 or 2 diabetes mellitus with DME and central involvement were enrolled. Eyes were treated with either macular laser photocoagulation or aflibercept as five initial 2 mg intravitreal monthly injections followed by either 2 mg every 4 weeks or 2 mg every 8 weeks. The primary efficacy endpoint was change from baseline in BCVA ETDRS letters at week 52. In both VISTA and VIVID from baseline to week 52 the mean BCVA gains were significantly greater with aflibercept treatment (p<0.0001) (see Table 2 ). Similar significant efficacy was observed in BCVA gains in both studies (p<0.0001). In addition, mean reductions in central retinal thickness (CRT) were significantly higher in patients treated with aflibercept (p<0.0001).
The incidence of serious adverse events including the Anti-Platelet
Trialists' Collaboration-defined arterial thromboembolic events and vascular deaths and ocular and nonocular adverse events were similar in all treatment groups. In particular, no cases of endophthalmitis or events suggestive of it such as hypopyon were observed.
Dexamethasone Intravitreal Implant
Two randomized, multicenter, masked, sham-controlled phase III clinical trials of dexamethasone intravitreal implant with identical protocols were completed and data pooled for analysis (Ozurdex MEAD study group). 4 A total of 1,048 DME patients with BCVA 20/50 to 20/200 Snellen equivalent and CRT ≥300 µm by OCT were randomized in a 1:1:1 ratio to dexamethasone intravitreal implant 0.7 mg, 0.35 mg or sham procedure with a 3-year follow-up and ≤40 scheduled visits. Patients could be retreated no more often than every 6 months and laser treatment was not used in these studies. Patients treated at month 36 were followed for 39 months. The achievement of ≥15 ETDRS letters improvement in BCVA from baseline to the end of study was the predefined US Food and Drug Administration (FDA) primary efficacy endpoint. Over the 3 years of the study the mean number of treatments given was similar between groups (see Table 3 ). Patients treated with either dose of dexamethasone achieved a greater 15-letter improvement in BCVA and in the average 
Fluocinolone Acetonide
The Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study assessed the long-term efficacy and safety of intravitreal implants that released either 0.2 µg/day (low dose) or 0.5 µg/day (high dose) in patients with DME. 5 The study included two randomized, sham injection-controlled, Table 4 , Figure 1) . A pre-planned subgroup analysis of patients who reported DME for ≥3 years at baseline indicated a doubling of benefit compared with sham injections. In addition, fluocinolone-treated patients showed an improvement in ≥2 steps in the ETDRS retinopathy scale. In the low-dose group, 13.7 % of patients showed a ≥2 step improvement compared with 10.1 % in the high-dose group and 8.9 % in the sham group.
This finding in the high-dose group may be because it released the drug for about 24 months, whereas the low-dose implant did so for 36 months and no retreatment was permitted. The majority of phakic patients treated with fluocinolone developed cataracts but following cataract surgery their visual benefit was similar to the pseudophakic patients. At 36 months incidence of incisional IOP-lowering surgery was 4.8 % and 8.1 % for the low-and high-dose groups, respectively, in a population that had to meet the current FDA label, which aims to mitigate the risk for IOP-lowering surgery.
There were several differences in the baseline characteristics from the phase III clinical trials that were the basis for the approval of the therapies.
The most important ones are in the patients enrolled in the FAME study evaluating fluocinolone, where the percentage of patients who received prior macular laser is higher, but the mean duration of DME (3 years) was considerably longer than in the other trials.
Optimum Use of the Available Therapies in Clinical Practice
The availability of several therapies for the treatment of DME is beneficial but presents retinal specialists with the problem of determining how to use them in clinical practice. The current standard of care for clinically significant DME is anti-VEGF therapy. A doctor will generally start anti-VEGF therapy unless there is a clearly defined circinate exudate emanating from a defined microaneurysm outside the fovea. However, several confirmatory lines of evidence suggest that although many patients gain significant benefit from anti-VEGF therapy, a considerable number do not.
The 36-month results of the RISE and RIDE trials showed an interesting difference in patients treated with ranibizumab from the start of the trials compared with sham-treated patients who were eligible to cross over to monthly 0.5 mg ranibizumab, although they were still masked. 6 In the ranibizumab groups, VA outcomes at month 24 were maintained at 36 months and, similarly, improvement in CFT after 24 months was generally sustained. By contrast, patients switched to ranibizumab 5, 36 suggests that delayed treatment does not give the same VA improvement and supports the hypothesis that anti-VEGF therapy is effective when administered in the early disease stages.
Research has shown that as DME progresses, upregulation of inflammatory cytokines occurs and these cytokines have multiple interactions that impact the pathogenesis of the disease. These findings reinforce the observations in the RIDE and RISE studies that anti-VEGF agents are useful in the early stages of disease when simple mechanisms induce edema, whereas at advanced stages, corticosteroids affect a greater number of inflammatory pathways. Patients will present with a range of inflammatory states and the most direct way to assess if their DME is primarily mediated by VEGF is to commence treatment with an anti-VEGF therapy.
Not all patients respond to anti-VEGF therapy. Available data, such as from the DRCR.net protocol I, indicate that approximately half of the patients are not optimally responding. 1 In addition in this study about 26 % were nonresponders. In the DRCR protocol T study of 660 adults with DME, comparing the relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of DME, there were nonresponders in each treatment group. Improvement of ≥15 ETDRS The ability to identify factors associated with relatively good or poor outcomes would be useful to treating ophthalmologists to make more informed decisions on which patients should be treated with anti-VEGF therapy and for patient expectations. To address this question, an additional analysis of 361 eyes assigned to 0.5 mg ranibizumab (either with prompt or deferred laser) was undertaken to identify risk factors that predict treatment success or failure. 13 A total of 37 baseline demographic, systemic, ocular, OCT, and fundus variables were assessed in terms of change in VA or OCT from baseline to year 1. Factors associated with either poor VA outcomes or OCT CSF thickness could not be evaluated as the number of patients with vision loss or increased CSF thickness were too small to analyze. However, after adjusting for baseline VA, younger age (p<0.001), absence of surface wrinkling retinopathy (p<0.001), and less-severe diabetic retinopathy were associated with a larger VA benefit.
In addition, central subfield thickness during the first year of treatment also predicted better vision outcomes (p>0.001).
Although laser photocoagulation has been the main treatment for DME and reduces the risk for further vision loss, vision improvement is rare,
occurring in approximately 12 % of patients after 3 years. Side effects include scotoma, altered colour perception, and night blindness. 14, 15 VEGF inhibitors demonstrate the ability to improve vision following multiple injections, but available data indicate that approximately 50 % of DME patients are not optimally managed on anti-VEGF therapy. 13 The upregulation of cytokines, rather than VEGF as the predominant mediator as diabetic retinopathy progresses, suggests that anti-VEGF therapies may not be the best management over the disease course. [16] [17] [18] [19] Shortacting intravitreal steroids also improve vision although are associated with an increased incidence of IOP elevations.
In the FAME study, treatment with the fluocinolone implant showed markedly greater benefit compared with the sham-treated group in patients with duration of DME ≥3 years than those with DME <3 years. 5 This finding suggests that eyes with persistent DME, which generally respond poorly to many treatments such as focal/grid laser photocoagulation, respond well to fluocinolone implants. It is unknown why sustained delivery of fluocinolone continues to provide benefit despite persistence of edema.
Possibly, persistent edema exacerbates inflammation in the diabetic retina and this is accompanied by bystander damage to retinal neurones and the exacerbation of inflammation in persistent DME may cause it to exceed a critical threshold causing cell death and vision loss. This inflammation could be reduced below the critical threshold by sustained levels of fluocinolone-preserving vision. Thus maximum benefit is not achieved in patients with persistent DME just by treating the anatomic distortion of the retina but inflammation must also be addressed. A further benefit is the regression in retinopathy grade via the reduction in inflammation observed in patients treated with fluocinolone implants.
Use of Anti-VEGF Therapy in Real Life
Data from the RIDE and RISE clinical trials was based on 36 monthly ranibizumab injections, but this injection frequency is uncommon in reallife situations. 16 In order to assess the clinical utilization of the anti-VEGF agents, bevacizumab and ranibizumab, together with disease monitoring in patients with branch or central vein occlusion or DME, a retrospective claims analysis has been completed. 21 A total of 2,733 DME patients were included. Over the 2008, 2009, and 2010 cohorts, the mean annual number of bevacizumab injections increased (2.2, 2.5, 3.6, respectively) with mean ophthalmologist visits ranging from 4.4 to 6.5 and mean OCT examinations from 3.1 to 3.9. In addition, 57.7 % of patients received additional laser or intravitreal triamcinolone. Too few ranibizumab patients were identified for a meaningful analysis mainly because it was not reimbursed by health plans until after its approval for DME in August 2012. Even in the most recent 2010 cohort, including patients followed through 2011, <6 % of patients met the criteria for monthly injections and <16 % for monthly ophthalmologist visits. These monitoring intervals are in sharp contrast to those reported in RISE and RIDE and the +6-week administration schedule in the DRCR.net phase II bevacizumab study. 22 The substantial differences in both injection frequency and the frequency of monitoring visits between the clinical studies and routine clinical practice suggests that in the clinical setting vision outcomes may be considerably lower than those reported in the clinical trials.
Furthermore, the RESTORE 12-month, double-masked, multicenter, lasercontrolled, phase III study investigated 0.5 mg intravitreal ranibizumab with either sham or active laser compared with laser and sham injections.
US OphthalMic REviEw
Although ranibizumab demonstrated significant superior change in BCVA letter score, only 22.6 % and 22.9 % of patients treated with ranibizumab or ranibizumab plus laser, respectively, gained a ≥15 BCVA letter score following seven injections. This is approximately half the percentage of patients responding in the RISE and RIDE trials probably reflecting the impact of fewer injections and more closely reflects real use.
Real-life US data are limited with ILUVIEN, but a small study is in progress in France and the initial findings are in line with the clinical trial data. 23 In addition, clinical experience with ILUVIEN has supported the results of the FAME study.
24

Translating the Clinical Trial Results to Clinical Practice
In clinical practice, retinal specialists use OCT as the primary driver of clinical decision-making. If the initial drug is anti-VEGF therapy and the doctor recognizes that optimal results are achieved with monthly injections, then after three to four treatments it should be possible to determine if a DME patient is an anti-VEGF responder by whatever criteria is chosen to claim effectiveness. For example, this could be complete resolution of edema or reduction in edema by a certain percent versus the baseline level. If the patient does not meet the criteria for response to an anti-VEGF therapy, possibly switching to another anti-VEGF treatment is an option since they have different levels of efficacy 12 or a corticosteroid should be considered.
If the decision is made to initiate treatment with a corticosteroid, it is highly likely that long-term therapy will be needed. In this situation, ILUVIEN provides 36 months of drug release with a single implant; however, the US indication requires a prior course of corticosteroid with no accompanying clinically significant rise in IOP (see Figure 2) . 25 At this point when use of a corticosteroid is indicated, an option for the retinal specialist is to try an Ozurdex implant or an intravitreal triamcinolone acetate injection (typically 1 or 2 mg), which will indicate whether the patient's edema is responsive to a corticosteroid as well as the IOP response to an ocular steroid. 26 The Ozurdex implant contains 700 μg of dexamethasone (in the The FAME clinical trials-analyses that supported the US indicationexamined the IOP-lowering surgeries as a function of previous ocular steroid prior to study entry. The following factors were identified:
• All of the IOP-lowering surgeries occurred in those subjects with no prior history of ocular steroid injection.
• The exclusion criteria stated that a patient could not have a history of an "uncontrolled IOP response to a corticosteroid" that did not respond to topical therapy. 
ADVERSE REACTIONS
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure. 
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
DOSAGE AND ADMINISTRATION
General Dosing Information
For ophthalmic intravitreal injection.
Administration
The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.
The injection procedure for ILUVIEN is as follows:
1. The exterior of the tray should not be considered sterile. An assistant (nonsterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit.
If acceptable, the assistant should peel the lid from the tray without touching the interior surface.
2. Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside.
3. Remove the applicator from the tray with sterile gloved hands touching only the sterile interior tray surface and applicator.
The protective cap on the needle should not be removed until the patient is ready to be injected.
Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator.
4. To reduce the amount of air administered with the implant, the administration procedure requires two steps. Before inserting the needle into the eye, push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position. If the button does not rise to the UP position, do not proceed with this unit.
5. Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye. Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera.
6. Carefully remove the protective cap from the needle and inspect the tip to ensure it is not bent.
7. Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle. Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.
DOSAGE FORMS AND STRENGTHS
ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 μg/day and lasting 36 months.
CONTRAINDICATIONS
Ocular or Periocular Infections
ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
Glaucoma
ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.
Hypersensitivity
ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.
WARNINGS AND PRECAUTIONS
Intravitreal Injection-related Effects
Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection [see Patient Counseling Information (17) ].
Steroid-related Effects
Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.
Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
Risk of Implant Migration
Patients in whom the posterior capsule of the lens is absent o of implant migration into the anterior chamber.
6 ADVERSE REACTIONS
Clinical Studies Experience
Because clinical trials are conducted under widely varyin reaction rates observed in the clinical trials of a drug canno to rates in the clinical trials of another drug and may not refl in practice.
Adverse reactions associated with ophthalmic steroids inclu cataract formation and subsequent cataract surgery, elevate which may be associated with optic nerve damage, visual ac secondary ocular infection from pathogens including herpes s of the globe where there is thinning of the cornea or sclera.
ILUVIEN was studied in two multicenter, randomized, sham-co in which patients with diabetic macular edema were treate (n=375) or sham (n=185). The most common ocular (study eye) and non-ocular advers in Tables 1 and 2 : 2 235 of the 375 ILUVIEN subjects were phakic at baselin controlled subjects were phakic at baseline. Concerns that inflammation caused by phacoemulsification can exacerbate DME have been raised, but patients with ILUVIEN have been shown to not have worse outcomes after surgery, most likely because steroids were already in the eye. 35 In the FAME study, the majority of patients (>95 %) did not require incisional surgery to treat elevated IOP and 62 % of patients did not require any IOPlowering medication during the 36-month study period.
Increased intraocular Pressure
5
Conclusion
Approximately 50 % of DME patients show varying degrees of suboptimal response to anti-VEGF therapy, as shown in several studies. In patients who do not adequately respond to this therapy, two corticosteroid dosage forms are also available. 13 In patients who do not adequately respond to this therapy, two corticosteroid dosage forms are also available. Before ILUVIEN can be used, the patient 
